Skip to main content

MGC Pharmaceuticals Ltd (LON:MXC) (ASX:MXC) said it has submitted a patent application for its CimetrA medical product to the Slovenian Intellectual Property Office (SIPO).

CimetrA is designed to treat multiple ailments including viral infections with acute and chronic inflammation, COVID-19 and variants of influenza, autoimmune diseases, adverse events resulting from the various forms of cancer therapy, and the promotion of an immune response to bacterial, viral, fungal and parasitic infections.

Close Menu